Benefits
DashboardNot registered yet? Get a free account.
Sign UpNot registered yet? Get a free account.
Sign Up
You're about to leave our website and go to an external link. Are you sure?
The company develops, manufactures, and supplies active pharmaceutical ingredient (API) such as dronedarone hydrochloride, phytonadione (Vitamin K1) etc.
Enaltec Labs Private Limited, is an unlisted private company incorporated on 24 February, 2006. It is classified as a private limited company and is located in Thane, Maharashtra. It's authorized share capital is INR 112.00 cr and the total paid-up capital is INR 57.00 cr.
Read more
Buy Dashboard using Credits
This action will use 1 of your credits. Are you sure you want to go ahead?
Credits Balance:
0
** All rupee values in INR crores. Based on March 2023 numbers.
-1.92%
63.51%
-34.53%
-7.48%
-11.18
-7.89
-6.63
1.84
-2.55
-1.55
Buy Report or Plans
Company dashboard
Five year financials and ratios
Risk analysis
Interactive charts
All financials
All annual returns
MoA and AoA
Latest financials
Latest annual return
MoA and AoA
Five year financials and ratios
Shareholding and group structure
Litigation and more
Everything in financial report
Peers and financials
* GST not included
** Reports & MCA filings will be based on the latest available financials.
India
(10)
| State | Type | Address |
|---|
Locations on Map
Filter (4)
Severe Risk
Moderate Risk
Low Risk
Read more
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | |
|---|---|---|---|---|---|
| Sales | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Operating profit | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Net profit | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Gross margin | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Operating margin | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Net margin | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Networth | |||||
| Borrowings | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Assets | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Debt to equity | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Current ratio | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| ROE | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Days payable | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| WC days | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | |
|---|---|---|---|---|---|
| Equity Capital | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Reserves | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Borrowings + | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Long term borrowings | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Short term borrowings | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Trade payables + | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Days payable | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Other liabilities + | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Other non-current liabilities | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Other current liabilities | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Total liabilities | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Fixed Assets + | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Tangible assets | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| CWIP | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Intangible assets | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| LT loans and advances | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Other non-current assets | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Current assets + | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Inventories | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Trade receivables | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Cash and cash equivalents | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| ST loans and advances | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Other current assets | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Total assets | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | |
|---|---|---|---|---|---|
| Sales + | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Sales growth % | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Expenses + | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Cost of goods | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Employee cost | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Other costs | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Operating profit + | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Operating margin % | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Other income | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Interest | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Depreciation | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Exceptional items | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Profit before tax | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Tax | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Profit - disc. ops | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Net profit | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Net margin % | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | |
|---|---|---|---|---|---|
| Solvency + | |||||
| Total Debt/Equity | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Net Debt/Equity | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Total Debt/Assets | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Total Assets/Equity | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Liquidity + | |||||
| Current Ratio | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Quick Ratio | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Interest Coverage | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Performance | |||||
| Gross Margin | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Operating Margin | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Net Margin | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Return + | |||||
| Return on Equity | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Pre-tax ROCE | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Return on Assets | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Pre-tax ROIC | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Efficiency + | |||||
| Days Payable | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Days Inventory | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Days Receivable | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Fixed Asset Turnover | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Total Asset Turnover | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Working Capital | |||||
| Cash Conversion Cycle | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Working Capital Days | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
Axis Bank Limited
No. of Loans: 2
Total Amount : 119.7 cr
Union Bank of India
No. of Loans: 1
Total Amount : 112.7 cr
Saraswat Co-op Bank Ltd
No. of Loans: 1
Total Amount : 17.1 cr
BMW India Financial Services Private Limited
No. of Loans: 1
Total Amount : 1.2 cr
| Designation | Name | DIN/PAN | Tenure |
|---|---|---|---|
| Managing Director | Anand Prafulchandra Shah
Shareholder
|
00597145 | 18 years |
| Director | Amit Bansilal Jain | 01074947 | 3 years |
| Director | Samir Kumar | 01647790 | 3 years |
| Director | Vivek Gupta | 02334674 | 3 years |
| Nominee Director | Sumit Gupta | 06401402 | 8 years |
| Director | Neeraj Singh | 07611419 | 2 years |
| CS | Mahesh Maljibhai Fuliya | <HIDDEN> | 2 years |
| Name | Status | Paid up Capital | Common Directors | Address |
|---|---|---|---|---|
| GENLINK PHARMA INVESTMENTS PRIVATE LIMITED |
Active
|
1.0 L | 1 | Maharashtra |
| GENLINK PHARMA LLP |
Active
|
1.0 L | 1 | Maharashtra |
| ENALTEC PHARMA RESEARCH PRIVATE LIMITED |
Active
|
14.0 L | 6 | Maharashtra |
| VEDELIK HEALTHCARE PRIVATE LIMITED |
Amalgamated
|
8.2 Cr | 2 | Madhya Pradesh |
| RUSOMA HEALTHCARE PRIVATE LIMITED |
Active
|
14.5 Cr | 2 | Madhya Pradesh |
| STANFORD LABORATORIES PRIVATE LTD |
Active
|
20.0 L | 2 | Delhi |
| LA RENON HEALTHCARE PRIVATE LIMITED |
Active
|
49.7 Cr | 2 | Gujarat |
| SUNWAYS ROHTO PHARMACEUTICAL PRIVATE LIMITED |
Active
|
32.5 L | 1 | Gujarat |
| SYMBIOTEC LIFESCIENCES PRIVATE LIMITED |
Active
|
1.0 L | 1 | Madhya Pradesh |
| GENEFACT PRIVATE LIMITED |
Active
|
50.0 L | 1 | Gujarat |
| INVENGENE LIMITED |
Active
|
1.5 Cr | 1 | Maharashtra |
| FRIMLINE PRIVATE LIMITED |
Active
|
1.0 L | 1 | Gujarat |
| Name | State / Country | Incorporation Year | Paidup Capital |
|---|---|---|---|
| ENALTEC PHARMA RESEARCH PRIVATE LIMITED | Maharashtra | 2005 | ₹ 14.0 L |
| Enaltec Lab INC (USA) | United States | - | - |
The incorporation date of ENALTEC LABS PRIVATE LIMITED is 24 February, 2006
The authorized share capital of ENALTEC LABS PRIVATE LIMITED is INR ₹ 112.0 Cr.
The paid-up capital of ENALTEC LABS PRIVATE LIMITED is INR ₹ 57.0 Cr.
The registered address of ENALTEC LABS PRIVATE LIMITED is 401 4th Floor Kesar Solitaire Plot No 5 Sector 19 Sanpada N avi Mumbai Thane Thane Thane Maharashtra - 400705
The CIN number of ENALTEC LABS PRIVATE LIMITED is U73100MH2006PTC160020.
Expand
Delete
Collapse
See
details
